期刊文献+

肺鳞癌合并肺肉瘤样癌变治疗1例及文献复习

A case report and literature review treatment of squamous cell lung cancer combined with pulmonary sarcomatoid carcinoma
下载PDF
导出
摘要 肺鳞癌是非小细胞肺癌中的一种亚型,其特殊的临床病理特点及分子背景决定了其治疗的局限性。肺肉瘤样癌是一种非小细胞肺癌,包含肉瘤或肉瘤样分化的成分,一种由上皮组织和间叶组织混合形成的恶性肿瘤,代表了上皮和间充质分化的整体连续谱系,是一类分化差、临床进展迅速、极少见的肺部恶性肿瘤。二者同时存在较为少见,治疗也较为棘手。结合相关的文献复习,现对贵州医科大学附属人民医院呼吸与危重症医学科近来收治的1例诊断肺鳞癌合并肺肉瘤样癌变的患者相关临床资料进行分析,以期提高临床医生对该疾病的认识。 Squamous cell lung cancer is a unique histological subtype of non-small cell lung cancer,its special clinicopathological features and molecular background determine the limitation of its treatment,pulmonary sarcomatoid canceration is a type of non-small cell lung cancer,contains elements of sarcoma or sarcomatoid differentiation.A malignant tumor of mixed epithelial and mesenchymal tissue,represents a whole continuum of epithelial and mesenchymal differentiation.It is a kind of poorly differentiated lung malignant tumor with rapid clinical progress and rare occurrence.It is rare to have both,treatment is also tricky.Combined with relevant literature review,the clinical data of a patient diagnosed with squamous cell lung cancer complicated with pulmonary sarcomatoid canceration recently admitted to the Department of Respiratory and Critical Medicine of the Affiliated People’s Hospital of Guizhou Medical University were analyzed,in order to improve clinicians’understanding of the disease.
作者 龙运芝 张湘燕 邵松军 汪国雨 LONG Yunzhi;ZHANG Xiangyan;SHAO Songjun;WANG Guoyu(Graduate School of Guizhou Medical University,Guizhou Province,Guiyang550004,China;Department of Respiratory and Critical Medicine,Affiliated People’s Hospital of Guizhou Medical UniversityGuizhou Provincial People’s Hospital,Guizhou Province,Guiyang550002,China)
出处 《中国医药导报》 CAS 2022年第21期189-192,共4页 China Medical Herald
基金 贵州省中医药管理局中医药、民族医药科学技术研究课题(QZYY-2019-002) 贵州省人民医院博士基金项目(GZSYBS[2018]01号) 贵州省科学技术计划基金项目(黔科合基础-ZK[2021]一般346)。
关键词 肺鳞癌 肺肉瘤样癌 免疫治疗 病例报道 Squamous cell lung cancer Pulmonary sarcomatoid carcinoma Immunotherapy Case reports
  • 相关文献

参考文献5

二级参考文献45

  • 1滕晓东.对WHO 2004年版肺肿瘤组织学分类的体会[J].中华病理学杂志,2005,34(8):544-546. 被引量:31
  • 2吴一龙,蒋国梁,廖美琳,周清华,陆舜,王绿化,张力,无.非小细胞肺癌孤立性转移处理共识[J].循证医学,2007,7(2):109-111. 被引量:23
  • 3涂茜,黄信华,贾铭,闫慧敏,黄婵桃.肺巨细胞癌一例[J].放射学实践,2007,22(3):321-321. 被引量:5
  • 4Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
  • 5Chen Z, Fillmore CM, Hammerman PS, et al. Non-small cell lung cancers:a heterogeneous set of diseases[J]. Nat Rev Cancer, 2014, 14(8):535-546.
  • 6Zhou C, Wu YL, Chen G, et al. Beyond:a randomized, double-blind, placebo-controlled, multicenter, phase Ⅲ study of first-line carboplatin/paclitaxel plus bevacizumab or placebo in Chinese patients with advanced or recurrent nonsquamous non-small-cell lung cancer[J]. J Clin Oncol, 2015, 33(19):2197-2204.
  • 7Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small cell lung cancer (OPTIMAL, CTONG-0802):a multicentre, open-label, randomised, phase 3 study[J]. Lancet Oncol, 2011, 12(8):735-742.
  • 8Camidge DR, Pao W, Sequist LV. Acquired resistance to TKIs in solid tumours:learning from lung cancer[J]. Nat Rev Clin Oncol, 2014, 11(8):473-81.
  • 9Xia B, Herbst RS. Immune checkpoint therapy for non-small-cell lung cancer:an update[J]. Immunotherapy, 2016, 8(3):279-298.
  • 10Creelan BC. Update on immune checkpoint inhibitors in lung cancer[J]. Cancer Control, 2014, 21(1):80-89.

共引文献961

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部